Genentech and Epizyme to study tazemetostat in Phase Ib/II combination trial for NSCLC

Roche Group ’s biotechnology subsidiary Genentech has expanded clinical collaboration with biopharmaceutical firm Epizyme to investigate the combination of atezolizumab (Tecentriq) and tazemetostat in a Phase Ib/II clinical trial to treat non-small-ce…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news